Biochem/physiol Actions

Reversible: no

Primary TargetCatalytic activity of topoisomerase II

Product does not compete with ATP.

Cell permeable: yes

Target IC₅₀: 20 µM for purified topoisomerase II (topo II)

General description

A cell-permeable, anticancer drug that inhibits the catalytic activity of DNA topoisomerase II (topo II) without damaging DNA or stabilizing DNA-topo II cleavable complexes (IC₅₀ = 20 µM for purified mammalian topoisomerase II versus IC₅₀ ~200 µM for topoisomerase I). Also induces apoptosis in human leukemic CEM cells through a caspase-3-like protease-dependent mechanism.

A cell-permeable anticancer drug that inhibits the catalytic activity of topoisomerase II (topo II) without damaging DNA or stabilizing DNA-topo II cleavable complexes (IC₅₀ = 20 µM for purified mammalian topo II versus IC₅₀ = ~ 200 µM for topo I). Also induces apoptosis in human leukemic CEM cells through a caspase-3-like protease-dependent mechanism.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Khelifa, T., and Beck, W.T. 1999. Mol. Pharmacol. 55, 548.Drake, F.H., et al. 1989. Cancer Res.49, 2578.Brewer, A.D., et al. 1985. Biochem. Pharmacol.34, 2047.

Packaging

Packaged under inert gas

25 mg in Plastic ampoule

Warning

Toxicity: Standard Handling (A)